These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21663507)

  • 21. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
    J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology.
    Hartmann S; Eray M; Döring C; Lehtinen T; Brunnberg U; Kujala P; Vornanen M; Hansmann ML
    BMC Cancer; 2014 May; 14():332. PubMed ID: 24885870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival.
    Alonso C; Dutta SW; Mitra N; Landsburg DJ; Zaorsky NG; Grover S; Peterson J; Trifiletti DM
    Cancer Med; 2018 Apr; 7(4):1118-1126. PubMed ID: 29479868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
    Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
    Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
    Olszewski AJ; Shrestha R; Cook NM
    Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
    Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT
    Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations.
    Agaimy A; Wild V; Märkl B; Wachter DL; Hartmann A; Rosenwald A; Ihrler S
    Am J Surg Pathol; 2015 Sep; 39(9):1206-12. PubMed ID: 25929348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.
    Pinnix CC; Milgrom SA; Cheah CY; Gunther JR; Ludmir EB; Wogan CF; Nastoupil LJ; Neelapu SS; Westin J; Lee HJ; Iyer SP; Steiner RE; Fayad LE; Fowler NH; Wang ML; Samaniego F; Rodriguez MA; Rich AE; Medeiros LJ; Dabaja BS
    Blood Adv; 2019 May; 3(9):1356-1367. PubMed ID: 31036721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [IF-RT alone remains gold standard for stage IA nodular lymphocyte-predominant Hodgkin lymphoma].
    Pilz K; Jentsch C; Krause M
    Strahlenther Onkol; 2016 Jun; 192(6):428-30. PubMed ID: 27194138
    [No Abstract]   [Full Text] [Related]  

  • 31. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
    Nogová L; Rudiger T; Engert A
    Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
    Borchmann S; Joffe E; Moskowitz CH; Zelenetz AD; Noy A; Portlock CS; Gerecitano JF; Batlevi CL; Caron PC; Drullinsky P; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Moskowitz AJ; Owens CN; Palomba ML; Younes A; Straus DJ
    Blood; 2019 May; 133(20):2121-2129. PubMed ID: 30770396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East.
    Akhtar S; Rauf MS; Khafaga Y; Al-Kofide A; Elhassan TAM; Elshenawy MA; Nadri J; Mushtaq AH; Bakshi N; Shamayel M; Al-Sweedan S; Sarwar S; Maghfoor I
    BMC Cancer; 2021 Apr; 21(1):351. PubMed ID: 33794818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Binkley MS; Advani RH
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):471-476. PubMed ID: 37076366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nodular lymphocyte predominant Hodgkin lymphoma at atypical locations may be associated with increased numbers of large cells and a diffuse histologic component.
    Yang DT; Dunphy CH; Tripp SR; Lagoo AS; Perkins SL
    Am J Hematol; 2008 Mar; 83(3):218-21. PubMed ID: 17918256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant.
    Drakos E; Rassidakis GZ; Leventaki V; Cotta CV; Vega F; Medeiros LJ
    Am J Surg Pathol; 2009 Nov; 33(11):1725-31. PubMed ID: 19730363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
    Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
    Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
    Strati P; Cheng PTM; Steiner RE; Alcedo Andrade PE; Feng L; Sano D; Rao VA; Singh P; Miranda R; Gunther JR; Pinnix CC; Dabaja BS; Cuglievan B; Xing K; Villa D; Skinnider B; Sehn LH; Connors JM; Nieto Y; Ahmed S; Lee HJ; Savage KJ
    Br J Haematol; 2021 Feb; 192(3):560-567. PubMed ID: 33517581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A high number of IgG4-positive plasma cells rules out nodular lymphocyte predominant Hodgkin lymphoma.
    Kiil K; Bein J; Schuhmacher B; Thurner L; Schneider M; Hansmann ML; Hartmann S
    Virchows Arch; 2018 Dec; 473(6):759-764. PubMed ID: 30259184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.